Change Summary - Form 2018 (R3) 1 of 12

Transcription

1 Summary - Form 2018 (R3) 1 of 12 Form Question Number (r3) Type Description New Text Previous Text Today's date was removed 2018 N/A Today's Date Removed from Key Fields 2018 N/A HCT Type 2018 N/A Product Type Option Value Option Value Syngeneic (identical twin) removed Question text changed Bone marrow PBSC Single cord blood unit Multiple cord blood units Other product Marrow PBSC Cord blood Other product Previous Question Number (r2) N/A N/A N/A What was the date of diagnosis? "What was the date of diagnosis of lymphoma?" was changed to "What was the date of diagnosis?" What was the date of diagnosis? What was the date of diagnosis of lymphoma? 1 Hodgkin Lymphoma Codes: 01 Nodular lymphocyte predominant Hodgkin lymphoma 02 Lymphocyte-rich 03 Nodular sclerosis 04 Mixed cellularity 05 Lymphocyte depleted 06 Hodgkin lymphoma, not otherwise specified Classical Hodgkin Lymphoma Codes: 01 Nodular lymphocyte predominant Hodgkin lymphoma 02 Lymphocyte-rich 03 Nodular sclerosis 04 Mixed cellularity 05 Lymphocyte depleted 06 Hodgkin lymphoma, not otherwise specified What was the lymphoma histology at diagnosis? Option Value Option values changed Non-Hodgkin Lymphoma Codes: B-cell Neoplasms 07 Splenic marginal zone B-cell lymphoma 08 Extranodal marginal zone B-cell lymphoma of mucosal associated lymphoid tissue type (MALT) 09 Nodal marginal zone B-cell lymphoma (± monocytoid B-cells) 10 Follicular, predominantly small cleaved cell (Grade I follicle center lymphoma) Non-Hodgkin Codes: 07 Lymphoplasmacytic lymphoma 08 Splenic marginal zone B-cell lymphoma 09 Extranodal marginal zone B-cell lymphoma of mucosal associated lymphoid tissue type (MALT) 10 Nodal marginal zone B-cell lymphoma (± monocytoid B-cells) 11 Follicular, predominantly small cleaved cell (Grade I follicle center lymphoma) 11 Follicular, mixed, small cleaved and large cell (Grade II follicle center lymphoma) 12 Follicular, mixed, small cleaved and large cell (Grade II follicle center lymphoma) 12 Follicular, predominantly large cell (Grade IIIA follicle center lymphoma) 13 Follicular, predominantly large cell (Grade IIIB follicle center lymphoma) 14 Follicular (grade unknown) 15 Mantle cell lymphoma 16 Intravascular large B-cell lymphoma 17 Primary mediastinal (thymic) large B-cell lymphoma 18 Primary effusion lymphoma 19 Diffuse, large B-cell lymphoma NOS 20 Primary diffuse, large B-cell lymphoma of the CNS 13 Follicular, predominantly large cell (Grade III follicle center lymphoma) 14 Follicular (grade unknown) 15 Mantle cell lymphoma 16 Diffuse, large B-cell lymphoma intravascular large B-cell lymphoma subtype 17 Diffuse, large B-cell lymphoma mediastinal large B-cell lymphoma subtype 18 Diffuse, large B-cell lymphoma primary effusion lymphoma subtype 19 Diffuse, large B-cell lymphoma subtype unknown 20 Burkitt lymphoma / Burkitt cell leukemia 21 High grade B-cell lymphoma, Burkitt-like (provisional entity) 2

2 Summary - Form 2018 (R3) 2 of Burkitt lymphoma 22 B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and Burkitt lymphoma 23 B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and classical Hodgkin Lymphoma 24 T-cell / histiocytic rich large B-cell lymphoma 25 Other B-cell lymphoma T-cell and NK-cell Neoplasms 26 Extranodal NK / T-cell lymphoma, nasal type 27 Enteropathy-type T-cell lymphoma 28 Hepatosplenic T-cell lymphoma 29 Subcutaneous panniculitis-like T-cell lymphoma 30 Mycosis fungoides 31 Sezary syndrome 32 Primary cutaneous CD30+ T-cell lymphoproliferative disorders [Primary cutaneous anaplastic large-cell lymphoma (C-ALCL), lymphoid papulosis] 33 Peripheral T-cell lymphoma (PTCL), NOS 34 Angioimmunoblastic T-cell lymphoma 35 Anaplastic large-cell lymphoma (ALCL), ALK positive 36 Anaplastic large-cell lymphoma (ALCL), ALK negative 37 T-cell large granular lymphocytic leukemia 38 Aggressive NK-cell leukemia 39 Adult T-cell lymphoma / leukemia (HTLV1 associated) 40 Other T-cell / NK-cell lymphoma 22 Primary CNS lymphoma 23 Other B-cell lymphoma 24 Extranodal NK / T-cell lymphoma, nasal type 25 Enteropathy-type T-cell lymphoma 26 Hepatosplenic gamma-delta T-cell lymphoma 27 Subcutaneous panniculitis-like T-cell lymphoma 28 Mycosis fungoides 29 Sezary syndrome 30 Anaplastic large-cell lymphoma, T / null cell, primary cutaneous type 31 Angioimmunoblastic T-cell lymphoma 32 Anaplastic large-cell lymphoma, T / null cell, primary systemic type 33 Other T-cell / NK-cell lymphoma 34 Large T-cell granular lymphocytic leukemia 35 Aggressive NK-cell leukemia 36 Adult T-cell lymphoma / leukemia (HTLV1 associated) 37 Waldenstrom macroglobulinemia Specify other lymphoma: "Specify:" was changed to "Specify other lymphoma:" Specify other lymphoma: Specify: Were immunohistochemical stains obtained? New Question N/A ALK-1 (Anaplastic Lymphoma Kinase 1) New Question N/A BCL-2 New Question N/A BCL-6 New Question N/A CD5 New Question N/A CD10 New Question N/A CD20 New Question N/A CD23 New Question N/A CD30 New Question N/A CD43 New Question N/A CD103 New Question N/A Cyclin D1 New Question N/A Ki-67 New Question N/A MUM1 New Question N/A Pax-5 New Question N/A Was flow cytometry (immunophenotyping) performed? New Question N/A CD1 New Question N/A CD2 New Question N/A CD3 New Question N/A CD4 New Question N/A CD5 New Question N/A CD7 New Question N/A CD8 New Question N/A CD10 New Question N/A CD20 New Question N/A CD19 New Question N/A CD22 New Question N/A CD23 New Question N/A

3 Summary - Form 2018 (R3) 3 of CD103 New Question N/A Cytoplasmic CD3 New Question N/A Cytoplasmic kappa New Question N/A Cytoplasmic lambda New Question N/A Kappa New Question N/A Lambda New Question N/A TCR α-β New Question N/A TCR γ-δ New Question N/A Were cytogenetics tested (conventional or FISH)? New Question N/A t(1;14) New Question N/A t(2;5) New Question N/A t(2;8) New Question N/A t(8;14) New Question N/A t(8;22) New Question N/A t(11;14) New Question N/A t(11;18) New Question N/A t(14;18) New Question N/A i(7q)(q10) New Question N/A Was documentation submitted to the CIBMTR? New Question N/A Were tests for molecular markers performed (e.g. PCR)? New Question N/A BCL-1/Cyclin D1, t(11;14) New Question N/A BCL-2, t(14;18) New Question N/A BCL-6 New Question N/A B-cell, Immunoglobulin Heavy (IgH) chain rearrangement New Question N/A T-cell receptor (TCR) gene rearrangement New Question N/A Other molecular marker(s) New Question N/A Specify other molecular marker(s): New Question N/A Was documentation submitted to the CIBMTR? New Question N/A WBC: New Question N/A WBC value New Question N/A Hemoglobin: New Question N/A Hemoglobin value New Question N/A Serum β2 microglobulin: New Question N/A Serum beta 2 value New Question N/A Upper limit of normal for serum β2 microglobulin New Question N/A Was a gene expression profile performed? New Question N/A Were results considered high risk lymphoma? New Question N/A

4 Summary - Form 2018 (R3) 4 of Was a PET (or PET/CT) scan performed? New Question N/A Was the PET (or PET/CT) scan positive for lymphoma involvement at any disease site? New Question N/A Did the recipient have known nodal involvement? New Question N/A Specify the total number of nodal regions involved: New Question N/A Specify the size of the largest nodal mass: New Question N/A Was there any known extranodal or splenic involvement? "Was there any known extranodal or splenic involvement at diagnosis?" was changed to "Was there any known extranodal or splenic involvement?" Was there any known extranodal or splenic involvement? Was there any known extranodal or splenic involvement at diagnosis? Specify other site(s): "Specify site:" was changed to "Specify other site(s):" Specify other site(s): Specify site: Stage of organ involvement: "Did the recipient have any known organ involvement at diagnosis:" was changed to "Stage of organ involvement:" Stage of organ involvement: Did the recipient have any known organ involvement at diagnosis: Stage of organ involvement: Option Value Option values changed I Involvement of a single lymph node region or of a single extralymphatic organ or site II Involvement of two or more lymph node regions on same side of diaphragm or localized involvement of extralymphatic organ or site and one or more lymph node regions on same side of diaphragm. III Involvement of lymph node regions on both sides of diaphragm, which may also be accompanied by localized involvement of extralymphatic organ or site, or the spleen, or both IV Diffuse or disseminated involvement of one or more extralymphatic organs in tissues with or without associated lymph node enlargement Unknown I Involvement of a single lymph node region or of a single extralymphatic organ or site II Involvement of two or more lymph node regions on same side of diaphragm or localized involvement of extralymphatic organ or site and one or more lymph node regions on same side of diaphragm. III Involvement of lymph node regions on both sides of diaphragm, which may also be accompanied by localized involvement of extralymphatic organ or site, or the spleen, or both IV Diffuse or disseminated involvement of one or more extralymphatic organs in tissues with or without associated lymph node enlargement Other organ involvement Unknown Were systemic symptoms (B symptoms) present? (unexplained fever > 38 C; or night sweats; unexplained weight loss > 10% body weight in six months before diagnosis) "Did the recipient show any systemic symptoms at diagnosis:" was changed to "Were systemic symptoms (B symptoms) present? (unexplained fever > 38 C; or night sweats; unexplained weight loss > 10% body weight in six months before diagnosis)" Were systemic symptoms (B symptoms) present? (unexplained fever > 38 C; or night sweats; unexplained weight loss > 10% body weight in six months before diagnosis) Did the recipient show any systemic symptoms at diagnosis: 11

5 Summary - Form 2018 (R3) 5 of What scale was used to determine the recipients functional status? Is the non-hodgkin lymphoma histology reported at diagnosis (question 2) a transformation from CLL? Was histologic transformation (not from CLL) detected at the same time or at any time after the lymphoma diagnosis (question 2)? What was the lymphoma histology at transformation? Was the date of transformation the same as the date of Other Karnofsky/Lansky scale questions were reformatted 30 "Is the current histology a transformation from CLL?" was changed to "Is the non- Hodgkin lymphoma histology reported at diagnosis (question 2) a transformation Is the non-hodgkin lymphoma histology reported at diagnosis (question 2) a from CLL?" transformation from CLL? Is the current histology a transformation from CLL? 4 "Did histologic transformation occur after diagnosis?" was changed to "Was histologic transformation (not from CLL) detected at the same time or at any time after the lymphoma diagnosis Was histologic transformation (not from CLL) detected at the same time or (question 2)?" at any time after the lymphoma diagnosis (question 2)? Did histologic transformation occur after diagnosis? 5 "Latest histology:" was changed to "What was the lymphoma histology at transformation?" What was the lymphoma histology at transformation? Latest histology: diagnosis? New Question N/A Were immunohistochemical stains obtained? New Question N/A ALK-1 (Anaplastic Lymphoma Kinase 1) New Question N/A BCL-2 New Question N/A BCL-6 New Question N/A CD5 New Question N/A CD10 New Question N/A CD20 New Question N/A CD23 New Question N/A CD30 New Question N/A CD43 New Question N/A CD103 New Question N/A Cyclin D1 New Question N/A Ki-67 New Question N/A MUM1 New Question N/A Pax-5 New Question N/A Was flow cytometry (immunophenotyping) performed? New Question N/A CD1 New Question N/A CD2 New Question N/A CD3 New Question N/A CD4 New Question N/A CD5 New Question N/A CD7 New Question N/A CD8 New Question N/A CD10 New Question N/A CD19 New Question N/A CD20 New Question N/A CD22 New Question N/A

6 Summary - Form 2018 (R3) 6 of CD23 New Question N/A CD103 New Question N/A Cytoplasmic CD3 New Question N/A Cytoplasmic kappa New Question N/A Cytoplasmic lambda New Question N/A Kappa New Question N/A Lambda New Question N/A TCR α-β New Question N/A TCR γ-δ New Question N/A Were cytogenetics tested (conventional or FISH)? New Question N/A t(1;14) New Question N/A t(2;5) New Question N/A t(2;8) New Question N/A t(8;14) New Question N/A t(8;22) New Question N/A t(11;14) New Question N/A t(11;18) New Question N/A t(14;18) New Question N/A i(7q)(q10) New Question N/A Was documentation submitted to the CIBMTR? New Question N/A Were tests for molecular markers performed (e.g. PCR)? New Question N/A BCL-1/Cyclin D1, t(11;14) New Question N/A BCL-2, t(14;18) New Question N/A BCL-6 New Question N/A B-cell, Immunoglobulin Heavy (IgH) chain rearrangement New Question N/A T-cell receptor (TCR) gene rearrangement New Question N/A Other molecular marker(s) New Question N/A Specify other molecular marker(s): New Question N/A Was documentation submitted to the CIBMTR? New Question N/A WBC: New Question N/A WBC value New Question N/A Hemoglobin: New Question N/A Hemoglobin value New Question N/A LDH: New Question N/A LDH value New Question N/A Upper limit of normal for LDH: New Question N/A Serum β2 microglobulin: New Question N/A Serum beta 2 value New Question N/A Upper limit of normal for serum β2 microglobulin New Question N/A

7 Summary - Form 2018 (R3) 7 of Was a gene expression profile performed? New Question N/A Were results considered high risk lymphoma? New Question N/A Was a PET (or PET/CT) scan performed? New Question N/A Was the PET (or PET/CT) scan positive for lymphoma involvement at any disease site? New Question N/A Was there any known extranodal or splenic involvement? New Question N/A Bone New Question N/A Bone marrow New Question N/A Brain New Question N/A Cerebrospinal fluid (CSF) New Question N/A Epidural space New Question N/A Gastrointestinal (GI) tract New Question N/A Kidney New Question N/A Liver New Question N/A Lung New Question N/A Pleura New Question N/A Skin New Question N/A Spleen New Question N/A Other site(s) New Question N/A Specify other site(s): New Question N/A Stage of organ involvement at transformation: New Question N/A Were systemic symptoms (B symptoms) present? New Question N/A What scale was used to determine the recipient s functional status: New Question N/A Karnofsky Scale (recipient age 16 years): New Question N/A Lansky Scale (recipient age < 16 years): New Question N/A Was therapy given? "Was therapy given between diagnosis and the start of the preparative regimen?" was changed to "Was therapy given?" Was therapy given? Was therapy given between diagnosis and the start of the preparative regimen? Systemic therapy: "Chemotherapy:" was changed to "Systemic therapy: Systemic therapy: Chemotherapy: 32

8 Summary - Form 2018 (R3) 8 of Date therapy started New Question N/A Date started: "Date therapy started:" was changed to "Date started" Date started: Date therapy started Date therapy stopped New Question N/A "Date therapy stopped:" was Date stopped: changed to "Date stopped:" Date stopped: Date therapy stopped Number of cycles: New Question N/A Number of cycles: Other "Unknown/not applicable" check box was removed ABVD (Doxorubicin, Bleomycin, Vinblastine, Dacarbazine) New Question N/A BEACOPP (Bleomycin, Etoposide, Doxorubicin, Cyclophosphamide, Vincristine, Procarbazine, Prednisone) New Question N/A CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) New Question N/A R-CHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) New Question N/A ESHAP (Etoposide, Methylprednisolone, Cytarabine, Cisplatin) New Question N/A DHAP (Dexamethasone, Cytarabine, Cisplatin) New Question N/A ICE (Ifosfamide, Mesna, Carboplatin, Etoposide) New Question N/A R-ICE (Rituximab, Ifosfamide, Mesna, Carboplatin, Etoposide) New Question N/A MOPP (Mechlorethamine, Vincristine, Procarbazine, Prednisone) New Question N/A

9 Summary - Form 2018 (R3) 9 of Stanford V (Doxorubicin, Vinblastine, Mechlorethamine, Vincristine, Bleomycin, Etoposide, Prednisone) New Question N/A Bendamustine New Question N/A Bortezomib (Velcade) New Question N/A Brentuximab New Question N/A Doxorubicin liposomal (Doxil) New Question N/A Everolimus (RAD-001) New Question N/A Interferon New Question N/A Lenalidomide (Revlimid) New Question N/A Ofatumumab (Arzerra, HuMAX-CD20) New Question N/A Photopheresis New Question N/A Pralatrexate New Question N/A Romidepsin New Question N/A Targretin New Question N/A Temsirolimus (Torisel) New Question N/A Vinorelbine (Navelbine) New Question N/A Vorinostat New Question N/A 2018 N/A Other monoclonal antibody Removed N/A Specify other antibody Removed 41 "Other treatment" was Other systemic therapy changed to "Other systemic therapy" Other systemic therapy Other treatment Specify other systemic therapy: "Specify other treatment:" was changed to "Specify other systemic therapy:" Specify other systemic therapy: Specify other treatment: 64 "Was this line of therapy given for stem cell priming?" Was this line of therapy given for stem cell mobilization (priming)? was changed to "Was this line of therapy given for stem cell mobilization (priming)?" Was this line of therapy given for stem cell mobilization (priming)? Was this line of therapy given for stem cell priming? Date therapy started New Question N/A Date started: "Date therapy started:" was changed to "Date started" Date started: Date therapy started Date therapy stopped New Question N/A Date stopped: "Date therapy stopped:" was changed to "Date stopped:" Date stopped: Date therapy stopped What was the extent of the radiation field? New Question N/A

10 Summary - Form 2018 (R3) 10 of Abdominopelvic New Question N/A Cervical spine New Question N/A Inguinal New Question N/A Mediastinum / chest "Mediastinum" was changed to "Mediastinum / chest" Mediastinum / chest Mediastinum Specify other site(s) "Specify other site(s)" was changed to "Specify other site:" Specify other site: Specify other site(s): Dose per fraction: New Question N/A Total number of fractions: New Question N/A Total dose: New Question N/A Specify technique: New Question N/A Specify other technique: New Question N/A Date of surgery: New Question N/A "Specify other site(s)" was Specify other site(s) changed to "Specify other site:" Specify other site: Specify other site(s): Best response to line of therapy: Option Value Option values changed Complete remission (CR) Partial remission (PR) Stable disease (SD) Progressive disease (PD) Unknown Not assessed "Date response established:" was changed to "Date assessed:" Date assessed: Date response established: CR - Complete remission (CR) CRU - CR Undetermined (CRU) PR - Partial remission (PR) NR/SD - Stable disease (SD) Prog - Progressive disease (PD) Unknown Date assessed: Serum β microglobulin: New Question N/A Serum beta 2 value New Question N/A Upper limit of normal for serumβ microglobulin New Question N/A Was a PET (or PET/CT) scan performed after the most recent line of therapy or at the time of pre-hct evaluation? "Was a PET scan performed at any time between diagnosis and the start of the preparative regimen?" was changed to "Was a PET (or PET/CT) scan performed after the most recent line of therapy or at the time of pre- HCT evaluation?" Was a PET (or PET/CT) scan performed after the most recent line of therapy or at the time of pre-hct evaluation? Was a PET scan performed at any time between diagnosis and the start of the preparative regimen? 81 Was the PET (or PET/CT) scan positive for lymphoma involvement at any disease site? "Was a PET scan positive for lymphoma involvement at any disease site?" was changed to "Was the PET (or PET/CT) scan positive for lymphoma involvement at any disease site?" Was the PET (or PET/CT) scan positive for lymphoma involvement at any disease site? Was a PET scan positive for lymphoma involvement at any disease site? Were cytogenetics tested (conventional or FISH)? New Question N/A t(1;14) New Question N/A

11 Summary - Form 2018 (R3) 11 of t(2;5) New Question N/A t(2;8) New Question N/A t(8;14) New Question N/A t(8;22) New Question N/A t(11;14) New Question N/A t(11;18) New Question N/A t(14;18) New Question N/A i(7q)(q10) New Question N/A Were tests for molecular markers performed (e.g. PCR)? New Question N/A BCL-1/Cyclin D1, t(11;14) New Question N/A BCL-2, t(14;18) New Question N/A BCL-6 New Question N/A B-cell, Immunoglobulin Heavy (IgH) chain rearrangement New Question N/A T-cell receptor (TCR) gene rearrangement New Question N/A Other molecular marker(s) New Question N/A Specify other molecular marker(s): New Question N/A Did the recipient have known nodal involvement? "Did the recipient have known nodal involvement at the time of the pre-hsct disease status assessment?" was changed to "Did the recipient have known nodal involvement?" "Did the recipient have known extranodal involvement at the time of the pre-hsct disease status assessment?" was changed to "Was there any known extranodal or splenic involvement?" Did the recipient have known nodal involvement? Did the recipient have known nodal involvement at the time of the pre-hsct disease status assessment? Was there any known extranodal or splenic involvement? Was there any known extranodal or splenic involvement? Did the recipient have known extranodal involvement at the time of the pre- HSCT disease status assessment? Spleen New Question N/A Specify other site: "Specify site:" was changed to "Specify other site:" Specify other site: Specify site: N/A 2018 N/A Was molecular testing performed at the time of the pre-hsct disease status determination? Removed Question was removed 100 Specify the date molecular testing was performed: Removed Question was removed N/A Was disease detected? Removed Question was removed 102

12 Summary - Form 2018 (R3) 12 of N/A What was the sensitivity of the lymphoma to chemotherapy prior to the preparative regimen? (Report the response to the last chemotherapy given prior to HSCT; treatment must be given 6 months prior to HSCT.) (see disease state definitions at question 104) Removed Question was removed 103 What was the disease status? What was the disease status? Option Value "What was the disease remission state immediately prior to the preparative regimen?" was changed to "What was the disease status?" Option values changed What was the disease status? Disease Untreated PIF res - Primary induction failure resistant: NEVER in COMPLETE remission but with stable or progressive disease on treatment. PIF sen / PR1 - Primary induction failure sensitive: NEVER in COMPLETE remission but with partial remission on treatment. PIF unk - Primary induction failure sensitivity unknown CR1-1st complete remission: no bone marrow or extramedullary relapse prior to transplant CR2-2nd complete remission CR3+ - 3rd or subsequent complete remission REL1 unt - 1st relapse untreated; includes either bone marrow or extramedullary relapse REL1 res - 1st relapse resistant: stable or progressive disease with treatment REL1 sen - 1st relapse sensitive: partial remission (if complete remission was achieved, classify as CR2) What was the disease remission state immediately prior to the preparative regimen? 104 Disease Untreated PIF res..primary induction failure resistant: NEVER in COMPLETE remission but with stable or progressive disease on treatment. PIF sen / PR1 Primary induction failure sensitive: NEVER in COMPLETE remission but with partial remission on treatment. PIF unk..primary induction failure sensitivity unknown CR1 1st complete remission: no bone marrow or extramedullary relapse prior to transplant CR2..2nd complete remission CR3+.3rd or subsequent complete remission CRU1.1st complete remission undetermined: as above with the exception of persistent scan abnormalities of unknown significance CRU2 2nd complete remission undetermined CRU3+.3rd or subsequent complete remission undetermined REL1 unt..1st relapse untreated; includes either bone marrow or extramedullary relapse 104 REL1 unk - 1st relapse sensitivity unknown REL1 res..1st relapse resistant: stable or progressive disease with treatment REL2 unt - 2nd relapse untreated: includes either bone marrow or extramedullary REL1 sen.1st relapse sensitive: partial remission (if complete remission was relapse achieved, classify as CR2) REL2 res - 2nd relapse resistant: stable or progressive disease with treatment REL1 unk.1st relapse sensitivity unknown REL2 sen - 2nd relapse sensitive: partial remission (if complete remission REL2 unt..2nd relapse untreated: includes either bone marrow or achieved, classify as CR3+) extramedullary relapse REL2 unk - 2nd relapse sensitivity unknown REL2 res..2nd relapse resistant: stable or progressive disease with treatment REL3+ unt - 3rd or subsequent relapse untreated; includes either bone marrow or REL2 sen.2nd relapse sensitive: partial remission (if complete remission extramedullary relapse achieved, classify as CR3+) REL3+ res - 3rd or subsequent relapse resistant: stable or progressive disease with REL2 unk..2nd relapse sensitivity unknown treatment REL3+ unt..3rd or subsequent relapse untreated; includes wither bone marrow REL3+ sen - 3rd or subsequent relapse sensitive: partial remission (if complete or extramedullary relapse remission achieved, classify as CR3+) REL3+ res..3rd or subsequent relapse resistant: stable or progressive disease REL3+ unk - 3rd relapse or greater sensitivity unknown with treatment REL3+ sen.3rd or subsequent relapse sensitive: partial remission (if complete remission achieved, classify as CR3+) REL3+ unk.3rd relapse or greater sensitivity unknown Date assessed: Signature 2018 section Date: New Question "Date assessed:" was changed to "Date of the most recent assessment for disease status prior to the preparative regimen:" "Date:" added to signature section Date assessed: Date of the most recent assessment for disease status prior to the preparative regimen: 105 N/A